
Releases
Acousia Therapeutics Reports Success in ACOU085 Hearing Loss Trial
More than 90% of young patients undergoing cisplatin chemotherapy for testicular cancer developed sensorineural hearing loss in a recent study, yet a new small molecule drug, ACOU085, has shown clinical promise in preventing permanent damage to the inner ear, according to top-line results from the Phase 2a PROHEAR trial.























